Cysteine to serine mutations at the C481 site permits downstream signalling, including PLCγ2 and CARD11, activation, hence bypassing the inactive BTK promoting distal BCR signalling activation, resulting in tumour cell proliferation, and migration. This evidence concerns the gene BTK and neoplasm.